View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Suvoda
  1. Sponsored
November 1, 2021updated 07 Mar 2022 10:16am

How product innovation is shaping the future clinical trial

E.K. Koh, Chief Product Officer at Suvoda, on the different ways eClinical technology innovations are simplifying trial complexity for patients, site managers and sponsors

What have you learned from working in product innovation in other industries that you can bring to improve clinical trials?

Two things drive innovation. One is new technology that enables an existing problem to be solved differently in perhaps a much more efficient way. The other is shifts in markets which create new pain points, new opportunities, that we can now apply technology to. Those are the key drivers for innovation, and they apply to most markets, whether it is the clinical trial market, the broader healthcare market, financial services, or anything else. So, I think the experience I have driving innovation in other industries is very applicable here — the ability to spot new technologies and how that might apply to solving the current problems differently.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Where does Suvoda see an opportunity for innovation in clinical trials?

Suvoda is focused on the efficient management of patient and drug supply logistics in a clinical trial. There are a lot of opportunities to improve on both through continuous innovation in those areas. One way is to make the patient’s experience of the clinical trial much more integrated and seamless, right from enrolling them to the trial itself to how he or she reports back on the trial as it progresses. Another area is the drug supply chain itself. There is opportunity to improve visibility of drug logistics during the course of the trial.

What specifically is Suvoda doing in these areas?

In 2018 we released direct-to-patient drug shipping, which is a step towards making it easier for patients to participate in these trials. We have also released temperature excursion management which makes it easier for drug supply managers to manage temperature-sensitive drugs through the supply chain.

We are currently focused on providing a much more integrated patient journey for our customers. If you look at a trial, it starts with onboarding the patient and all the concerns that the patient needs to be apprised of before they consent to participate. Then the patient is enrolled, screened and assigned to a treatment arm. As the trial progresses, study teams want to capture the patient’s reported outcomes. Integrating patient consent and clinical outcome assessments with our IRT is the area that we are working on to create an enhanced and seamless patient experience. The other part is to make it easier for our sponsors or site managers to have better visibility to trial metrics, enabling real-time decisions and providing greater mid-trial control.

What are future trends in product innovation that will help shape clinical trials?

A big trend for us is the decentralisation and the virtualisation of trials. It has been happening for a while, but COVID has really accelerated that trend. It’s about bringing the trial to the patient, providing that flexibility. This goes all the way from site-centric, which is where we are today and where the patient comes to the trial site to participate in the trial, to the other end of the spectrum where the patient is fully remote. I think the reality is it’s going to be somewhere in between with some elements of the trial conducted on-site while others will be conducted remotely. So that level of flexibility needs to be available to the study teams in order to be able to bring drugs to market faster in a more cost-effective and efficient manner, and available to patients to make it easier for them to participate in trials. It’s very real and attainable. We want to have the digital tools to make that possible for patients and our site managers and sponsors.

What are you most excited about in this space and your role in it with Suvoda?

It is the opportunity to drive the transformation we have discussed through a platform-based approach. We can provide that platform to enable the digitisation of different parts of the patient journey to ensure that the patient experience is optimised and to ensure that the data we collect in each part of the journey is integrated. We also have the opportunity to make it easier for sponsors and study managers to manage all the different parts of the patient journey from one integrated platform. I think that’s what’s most exciting and that’s the opportunity for Suvoda and our customers, and we’re well-positioned to do that.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena